Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 3, 2002 - Issue 8
Submit an article Journal homepage
24
Views
0
CrossRef citations to date
0
Altmetric
Miscellaneous

Eradication of Helicobacter pylori: current perspectives

P Pandhi Department of Pharmacology, PGIMER, Sector 12, Chandigarh, India, Tel: +91 172 721 293; Fax: +91 172 744 401
&
Samir Malhotra Department of Pharmacology, PGIMER, Sector 12, Chandigarh, India, Tel: +91 172 721 293; Fax: +91 172 744 401
Pages 1031-1038 | Published online: 25 Feb 2005

Bibliography

  • PIPER DW, DE CARLE DJ, TALLEY NJ et al.: Gastrointestinal and hepatic diseases. In: AverYs Drug Treatment. Speight TM, Holford NHG (Eds), Adis International Limited, Auckland, New Zealand (1997):933–1021.
  • MARSHALL BJ, WARREN JR: Unidentified curved bacilli in the stomach of patients with gastritis and hepatic ulceration. Lancet (1984) 1:1311–1315.
  • •Landmark paper
  • SOLL AH: for the Practice Parameters Committee of the American College of Gastroenterology. Medical treatment of peptic ulcer disease. Practice guidelines. Am. Med. Assoc. (1996) 275:622–627.
  • MCQUAID KR: Alimentary tract. In: Current Medical Diagnosis and Treatment. Adult Ambulatory And Inpatient Management. Tierney LM Jr, McPhee SJ, Papadakis MA (Eds), Large Medical Books, New York, USA (2002):618–626.
  • MALHOTRA S: Regimens for the eradication of Helicobacter pylori. A `meta-analysis' of meta-analysis. Medscape Pharmacother. (2001).
  • •An interesting review of meta-analysis conducted for the treatment of H
  • WORKING PARTY OF THE EUROPEAN HELICOBACTER PYLORI STUDY GROUP: Guidelines for clinical trials in Helicobacter pylori infection. Gut (1997) 41\(Suppl. 2):51–59.
  • •This article is a must for all those intending to conduct clinical trials in H pylori infection.
  • MCNAMARA D, O'MORAIN C: Consensus guidelines agreement and debate surrounding the optimum management of Helicobacterinfection. Curr: Gastroenterol (2000) 14:511–517.
  • LEE JM, DEASY E, O'MORAIN CA: Helicobacter pylon eradication therapy: a discrepancy between current guidelines and clinical practice. him Gastroenterol (2000) 14:433–437.
  • CHIBA N, RAO BV, RADEMARKERJW, HUNT RH: Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori Am. J. Gastroenterol (1992) 87:1716–1727.
  • PETERSON WL, GRAHAM DY, MARSHALL B et al.: Clarithromycin as monotherapy for eradication of Helicobacter pylori:. a randomized double-blind trial. Am. Gastroenterol (1993) 88:1860–1864.
  • BARDHAN KD, DHALLAIRE C, EISOLD H, DUGGAN AE: Ranitidine bismuth citrate with clarithromycin for the treatment of duodenal ulcer. Gut (1997) 41:181–186.
  • DEBOER WA, TYTGAT GNJ: The best therapy for Helicobacter pyloriinfection. Should efficacy or side effect profile determine our choice? Scand. Gastroenterol (1995) 30:4017.
  • MARSHALL BJ, ARMSTRONG JA, FRANCIS GJ, NIKES NT, WEE SH: Antibacterial action of bismuth in relation to Campylobacter pylori colonization and gastritis. Digestion (1987) 37:16–30.
  • MCNULTY CA, DENT JC, FORD GA, WILKINSON SP: Inhibitory antimicrobial concentrations against Campylobacter pylori in the gastric mucosa. J. Antimicrob. Chemother. (1988) 22:729–738.
  • PENTSON JG: Helicobacter pylori eradication - understandable caution but no excuse for inertia. Aliment. Pharmacol Then (1994) 8:369–389.
  • Current European concepts in the management of Helicobacter pyloriinfection. The Maastricht Consensus Report. Gut (1997) 41:8–13.
  • RUNE S: Helicobacter pylori, peptic ulcer disease and inhibition of gastric acid secretion. Digestion (1992) 51:6–11.
  • BAZZOLI F, POZZATO P, ZAGARI M et al.: Efficacy of lansoprazole in eradicating Helicobacterpy/ori: a meta-analysis. Helicobacter (1998) 3:195–201.
  • DAJANI EZ, KLAMUT MJ: Novel therapeutic approaches to gastric and duodenal ulcers: an update. Expert Opin. Investig. Drugs (2000) 9:1537–1549.
  • HUANG AH, SHOU BS, YANG HB, HUANG CC, WV JJ, LIN XZ: Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy. I Formoes Med. Assoc. (2000) 99:704–709.
  • KAUSHIK SP, VU C: Helicobacter pylori eradication with lansoprazole, amoxycillin and clarithromycin testing an ideal regimen in a multicultural South East Asian population and examining factors potentially influencing eradication. Aust. NZ. J. Med. (2000) 30:231–235.
  • MOYYEDI P, FELTBOWER R, CROCOMBE W et al: The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in community screen and treat programme. Leeds Help Study Group. Aliment. Pharmacol Then. (2000) 14:719–728.
  • DAMMANN HG, FONSCH UR, HAHN EG et al: Eradication of H pylori with pantoprazole, clarithromycin and metronidazole in duodenal ulcer patients: a head to head comparison between two regimens of different duration. Helicobacter (2000) 5:41–51.
  • NVEV A, STIMAC D, IVANDIC A, VEEVA A,TAKAC B, PEZEROVIC D: Pantoprazole, amoxycillin and either azthromycin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. Aliment. Pharmacol Then (2000) 14:69–72.
  • FOCK KM, NG HS, NG TM, LAW NM, LIM CC: A randomized trial of amoxycillin versus clarithromycin in combination with omeprazole for eradication of Helicobacter pylori eradication in Singapore. Singapore Med. J. (2000) 41:482–484.
  • GISBERT JP, GONZALEZ L, CALVET X et al.: Proton pump inhibition, clarithromycin and either amoxycillin or nitroimidazole a meta-analysis of eradication of Heilcobactenpylonl. Aliment. Pharmacol Then. (2000) 14:1319–1328.
  • KATELARIS PH, ADAMTHWAITE D, MID OLO P, YEOMANS ND, DAVIDSON G, LAMBERT J: Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERD study. Ailment. Pharmacol Ther. (2000) 14:751–718.
  • DOBRUCALI A, CANBAKAN B, CANBAKAN M et al.: Meta analysis of determining the pathogen eradicating efficacy of various therapeutic regimens in Helicobacter pylori infection. Wien Med. Wochenschr. (1998) 48:464–468.
  • HOLTMANN G, LAYER P, GOEBELL H: Are proton pump inhibitors superior to H2 receptor antagonists within the scope of H pylori eradication therapy? Meta-analysis of current parallel group comparisons. Z Gastroenterol (1996) 34:267–272.
  • GISBERT JP, GONZALEZ L, CALVET X, ROQUE M, GABRIEL R, PAJARES JM: Helicobacter pylori eradication proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics for 1 week - meta-analysis of efficacy. Aliment. Pharmacol Then. (2000) 14:1141–1150.
  • TUNIS SR, SHENHAIT IA, SCHMID CH, BISHOP DJ, ROSS SD: Lansoprazole compared with histamine 2-receptor antagonists in healing gastric ulcers a meta-analysis. Clin. Then (1997) 19:743–737.
  • GARCIA N, CALVET X, GENE E, CAMPO R, BRULLET E: Limited usefulness of a seven-day twice-a-day quadruple therapy. Eui: I Gastroenterol Hepatol (2000) 12:1315–1318.
  • NAGAHARA A, MIWA H, YAMADAT, KUROSAWA A, OKHURA R, SATO N: Five-day proton pump inhibitor-based quadruple therapy is more effective than 7-day triple therapy regimen for Helicobacter py/oriinfection. Aliment. Pharmacol Then (2001) 15:417–421.
  • GRAHAM DY, OSATO MS, HOFFMAN J et al.: Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori a prospective study. Aliment. Pharmacol Then. (2000) 14:745–750.
  • CALVET X, TITOL, COMET R, GARCIA N, CAMPO R,BRULLET E: Four-day, twice daily, quadruple therapy with amoxicillin, clarithromycin, tinidazole and omeprazole to cure Helicobacter pylori infection - a pilot study. Helicobacter (2000) 5:52–56.
  • MICHOPOULOS S, TSIBOURI T, BOUSAKIS H et al.: Randomized study comparing omeprazole with ranitidine as anti-secretary agents combined in quadruple second-line Helicobacter pylori eradication regimens. Aliment. Pharmacol. Ther. (2000) 14:737–744.
  • DIMARIO F, BATTAGLIA F, DAL BO N et al: Cure of Helicobacter pylori-positive active duodenal ulcer patients: a double-blind, multicentre, 12-month study comparing a two-week dual versus a one week triple therapy. GISU (Interdisciplinary Group for Ulcer Study). Dig. Liver Dis. (2000) 32:108–119.
  • HURENKAMP GJ, VAN DER ENDE A, GRUNDMEUER HG, TYTGAT GN, VANDER HULST RW: Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease. Aliment. Pharmacol. Ther. (2000) 14:1065–1070.
  • BHASIN DK, SHARMA BS, RAY P, PATHAK CM, SINGH K: Comparison of seven and fourteen days of lansoprazole, clarithromycin and amoxicillin therapy for eradication of Helicobacter pylori: a report from India. Helicobacter (2000) 5:84–87.
  • CALVET X, GARCIA N, LOPEX T, GISBERT JP, GENE E, ROQUE M: A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithro-mycin and either metronidazole or omecycillin for treating Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2000) 14:603–609.
  • ZULLO A, RANALDI V, WINN Set al: Anew highly effective short term therapy scheduled for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. (2000) 14:715–718.
  • KAVIANI MJ, MALEKZADEH R, VAHEDI H et al: Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 to 2 weeks) on eradication of Helicobacter pylori in Iranian people ulcer patients of randomized controlled trial. Ear: .1. Gastroenterol. Hepatol (2001) 13:915–919.
  • WONG BC, WANG WH, WONG WM et al: Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study. Aliment. Pharmacol. Ther. (2001) 15:843–849.
  • OGURA K, YOSHIDA H, MAEDA S et al: Clarithromycin-based triple therapy for non-resistant Helicobacter pylorifactors. How long should it be given? Scand. .1. Gastroenterol. (2001) 36:584–588.
  • KAMBERGLOU P, POLYMEROS D, SANIDAS L et al: Comparison of 1-week US 2 or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. Ailment. Pharmacol. Ther. (2001) 15:1493–1497.
  • ELL C, SCHDERNER C, SOLBACH W et al.: The AMOR study: a randomized, double-blinded trial of omeprazole versus ranitidine together with amoxycillin and metronidazole for eradication of Helicobacter pylori Ear: Gastroenterol Hepatol. (2001) 13:685–691.
  • GISBERT JP, MARCOS S, GISBERT JL,PAJARES JM: High efficacy of ranitidine bismuth citrate, amoxicillin, clarithromycin and metronidazole twice daily for only five days in Helicobacter pylori eradication. Helicobacter (2001) 6:81–83.
  • NAKAJIMA S, GRAHAM DY, HATTORI T, BAMBA T: Strategy for treatment of Helicobacter pylorifactors in adults. I. Updated indications for test and eradication therapy suggested in 2000. Curr. Pharm. Des. (2000) 6:1503–1514.
  • PATTERSON WL, FENDRICK AM, CAVE DR, PEURA DA, GARABEDIAN-RUFFALO SM, LAINE L: Helicobacter py/ori-related disease: guidelines for testing and treatment. Arch. Intern. Med. (2000) 160:1285–1291.
  • MEINECHE-SCMIDT V, RUBIN G, DE WO NJ: Helicobacter pylori infection: a comparative review of existing management guidelines. Fam. Pract. (2000) 17\(Suppl. 2):S2–S5.
  • GRAHAM DY: Therapy of Helicobacter pylort current status and issues. Gastroenterology (2000) 118:82–88.
  • •An excellent review of some less obvious but very important issues.
  • SPRIET A, DUPIN-SPRIET T, SIMON P: Methodology of Clinical Trials Kaiger, Basel, Switzerland (1993):229–245.
  • CARRICK J: Problems with clinical trials on Carnpylabacter pylori j Clin. Gastroenterol (1988) 10:247–248.
  • HSU CC, CHEN JJ, HUTH, LV SN, CHANGCHEIN GS: Famotidine versus omeprazole in combination with amoxicillin and tinidazole for eradication of Helicobacter pyloriinfection. Ear: .1. Gastroenterol Hepatol. (2001) 13:921–926.
  • VAN DER WOUDEN EJ, THUS JC, VAN ZWET AA, SLUITER WJ, KLEIBEUKAR JH: The influence of In vitro nitroimidazole resistance on the efficacy of nitroimidazole containing anti- Helicobacter pylori regimens - a meta-analysis. Am. Gastroenterol. (1999) 94:1751–1759.
  • LEUNG WK, GRAHAM DY: Clarithromycin for Helicobacter pylori infection. Expert Opin. Pharmacother. (2000) 1:507–514.
  • MEYER JM, SILLIMAN NP,WANG Wet al: Risk factors for Helicobacter pylori resistance in the United States. The surveillance of H pylori Antimicrobial Resistance Partnership (SHARP) Study, 1993–1999. Ann. Int. Med. (2000) 136:13–24.
  • MOLLISON LC, STINGEMORE N, WAKE RA, CULLEN DJ, MCGECHIE DB: Antibiotic resistance in Helicobacter pylori Med. Aust. (2000) 173:508–509.
  • PAN ZJ, SU WW, TYTGAT GN, DANKERT J, VAN DER ENDE A: Assessment of clarithromycin resistant Helicobacter pylori among patients in Shanghai and Guangzhou, China by Primer-Mismatch PCR. I Clin. Microbiol. (2002) 40:259–261.
  • GRAHAM DY: Antibiotic resistance in Heticobacterpy/ori: implications for therapy. Gastroenterology (1998) 115:1272–1277.
  • MCNULTY CAM, GEARTYJC, CRUMP B et al: Camplylobacter pyloridis and associated gastritis: investigator-blind, placebo-controlled trial of bismuth salicylate and erythromycin methyl succinate. Br. Med. (1986) 293:645–649.
  • GRAHAM DY, BORSCH GMA: The who's and when's of therapy for Helicobacter pylori Am.j Gastroenterol. (1990) 85:1552–1554.
  • SOLL AH: Gastric, duodenal and stress ulcer. In: Gastrointestinal Disease. Scharscmidt BF, Feldman M (Eds), WB Saunders Company, Philadelphia, USA (1993):580–679.
  • RUAWS EJA, LANGENBERG W, HOUTHOFF HJ, ANEN HF, TYTGAT GNJ: Campylabacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and effect of antibacterial and antiulcer treatment. Gastroenterology (1988) 94:33–37.
  • MARSHALL BJ, WARREN JN, BLINCOW et al: Prospective double-blind trial of duodenal ulcer after eradication of Campylobacter pylori. Lancet (1988) 2:1437–1441.
  • RAUVVS EAJ, TYTGAT GNJ: Cure of duodenal ulcer associated with eradication of Helicobacter pylori Lancet (1990) 335:1233–1236.
  • GEOGRELL, BORODY TJ, ANDREWS P et al.: Cure of duodenal ulcer after eradication of Helicobacter pylori Med. Aust. (1990) 153:145–149.
  • GRAHAM DY: Helicobacter pylori. Its epidemiology and its role in duodenal ulcer disease.j Gastroenterol Hepatol (1991) 6:97–101.
  • GRAHAM DY, MALATU HM, EVANS DG et al.: Epidemiology of Helicobacter pylori in asymptomatic population in United States. Gastroenterol (1991) 100:1495–1498.
  • ASAKA M, KIMURA T, KUDO M et al.:Relationship of Helicobacter pylori to serum pepsinogen in an asymptomatic Japanese population. Gastroenterology (1992) 102:760–763.
  • GRAHAM DY, LEW GM, MACATY HM et al.: Factors influencing the eradication of Helicobacter pylon with triple therapy. Gastroenterology (1992) 102:493–496.
  • PERRI F, VILLAVI MR, FESAP V, QUITADAMOM, ANDRIULLI A: Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment. Pharmacol Ther. (2001) 15:1023–1029.
  • BATESON MC: Quadruple therapy for symptomatic duodenal ulcer disease. Postgrad. Med. (2001) 77:447–450.
  • AURIEMMA L, SIGNORELLI S: The roleof tetracycline in the retreatment after Helicobacter pylori eradication failure. Minerva Med. (2001) 92:145–149.
  • PHILLIPS RH, WHITEHEAD MW, DOIG LA et al.: Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe? Helicobacter (2001) 6:151–156.
  • NAGAHARA A, MIWA H, OKHURA R et al.: Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection. " Gastroenterol Hepatol (2001) 16:613–618.
  • ZULLO A,HASSAN C, CAMPO SM et al.: A triple therapy regimen after Helicobacter pylori treatments. Aliment. Pharmacol Ther. (2001) 15:1193–1197.
  • PERRI F, FESTA V, CLEMENTE R et al:Randomized study of two 'rescue' therapies for Helicobacter pylori - infected patients after failure of standard triple therapies. Am. Gastroenterol (2001) 96:58–62.
  • ADACHI K, ISHIHARA S, HASHIMOTO T et al.: Efficacy of sucralfate for Helicobacter pylori. eradication triple therapy in comparison with a lansoprazole-based regimen. Aliment. Pharmacol Ther. (2000) 14:919–922.
  • MCNULTY LA, WILSON MP, HAVINGA W, JOHNSTON B, O'GARA EA, MASLIN DT: A pilot study to determine the effectiveness of garlic oil capsules in the treatment of dyspeptic patients with Helicobacter Helicobacter (2001) 6:249–253.
  • SHUBER A, ASCANO JJ, BOYNTON KA et al.: Accurate, noninvasive detection of Helicobacter pyloriDNA from stool samples. Potential usefulness for monitoring treatment. Clin. Microbiol (2002) 40:262–264.
  • HOUGHTON J, RAMAMOORTHY R, PANDYA H, DHIRMALAM R, KIM KH: Human plasma is directly bacteriocidal against Helicobacter pylori in vitro, potentially explaining the decreased detection of Helicobacter pylori during acute upper GI bleeding. Gastrointest. Endosc. (2002) 55:11-16. Website This website is not referenced in the text but has been found useful by the author.

Websites

  • http:/www.medscape.com/Medscape/ Pharmacology/Journal/2001.V03.204/ mp0814.math/mp0814.malh.html
  • •Download [5] here.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.